Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Depreciation & Amortization (CF) (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Depreciation & Amortization (CF) for 7 consecutive years, with $202000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 20.96% year-over-year to $202000.0, compared with a TTM value of $700000.0 through Dec 2025, changed 0.0%, and an annual FY2025 reading of $700000.0, changed 0.0% over the prior year.
  • Depreciation & Amortization (CF) was $202000.0 for Q4 2025 at aTYR PHARMA, up from $165000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $202000.0 in Q4 2025 and bottomed at $39000.0 in Q4 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $135350.0, with a median of $163000.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) crashed 63.89% in 2022, then skyrocketed 369.23% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $108000.0 in 2021, then plummeted by 63.89% to $39000.0 in 2022, then surged by 369.23% to $183000.0 in 2023, then dropped by 8.74% to $167000.0 in 2024, then grew by 20.96% to $202000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for ATYR at $202000.0 in Q4 2025, $165000.0 in Q3 2025, and $166000.0 in Q2 2025.